細胞動力 CYTK 深 滬
已收盤 12-19 16:00:00 美东时间
62.72
+0.520
+0.84%
華盛通- 最 高63.70
- 今 開62.93
- 成交量 131.13万股
- 最 低 62.10
- 昨 收 62.20
- 總市值 76.52亿
- 52周最高 69.33
- 市盈率 靜 --
- 換手率 1.07%
- 52周最低 29.31
- 委 比 82.14%
- 總股本 1.22亿
- 歷史最高 110.25
- 量 比 0.66
- 振 幅 2.57%
- 歷史最低 0.57
- 每 手 1
- 風險率 10.65%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cytokinetics Receives FDA Approval For MYQORZO Tablets To Treat Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has approved MYQORZO™ (aficamten), 5 mg, 10 mg, 15 mg, 20 mg tablets for the treatment of adults with
12-20 05:01
Goldman Sachs Upgrades Cytokinetics to Buy, Raises Price Target to $95
Goldman Sachs analyst Paul Choi upgrades Cytokinetics (NASDAQ:CYTK) from Neutral to Buy and raises the price target from $55 to $95.
12-20 00:49
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cytokinetics granted 21,399 stock options and 14,422 restricted stock units (RSUs) to 10 new employees as inducements to their employment. The RSUs vest over 3 years, while the stock options vest over 4 years. Cytokinetics is a cardiovascular biopharmaceutical company advancing potential new medicines for heart conditions, including aficamten and omecamtiv mecarbil, which are in late-stage clinical trials.
12-16 21:00
美股大行评级 | 博通、Lululemon获10逾家大行上调目标价；好市多、RH遭大行下调目标价
今日重点评级关注：杰富瑞：维持ImmunityBio Inc Ordinary Shares"买入"评级，目标价从8美元升至9美元；B. Riley证券：维持WAVE Life Sciences"买入"评级，目标价从19美元升至37美元
12-15 15:30
ImmunityBio, Moderna among winners of EU drug recommendations this week
An expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed seven new medicines for approval this week, including a cancer drug from ImmunityBio (IBRX) and Moderna's (MRNA)...
12-12 23:45
Cytokinetics Receives EU Recommendation for MYQORZO®
Cytokinetics ( ($CYTK) ) just unveiled an announcement. On December 12, 2025, C...
12-12 22:17
Needham Reiterates Buy on Cytokinetics, Maintains $72 Price Target
Needham analyst Serge Belanger reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $72 price target.
12-12 18:56
Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy
The European Medicines Agency's CHMP has recommended marketing authorization for MYQORZO® (aficamten) in the EU for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults. This decision is based on positive Phase 3 trial results showing improved exercise capacity and safety. The European Commission is expected to finalize the decision in Q1 2026. MYQORZO is also under regulatory review in the U.S. and China, with a FDA PDUF...
12-12 13:42
What Does the Market Think About Cytokinetics Inc?
Cytokinetics Inc's (NYSE:CYTK) short interest as a percent of float has fallen ...
11-18 23:00
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cytokinetics announced the granting of stock options and restricted stock units (RSUs) to new employees, including Executive Vice President Jeffrey Hessekiel, as material inducements to their employment. The RSUs vest over three years, while the stock options vest over four years with a 10-year term. The company is advancing its pipeline of potential new medicines for cardiovascular diseases, with aficamten poised for regulatory approvals followi...
11-18 21:00
